Related Experiment Video
Updated: Aug 9, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 15, 2011
A recombinant fungal compound induces anti-proliferative and pro-apoptotic effects on colon cancer cells
Lili Nimri1, Orly Spivak1, Dana Tal1
1The Robert H. Smith Faculty of Agriculture, Food and Environment, Institute of Biochemistry, Food Science and Nutrition, The Hebrew University of Jerusalem, Rehovot 76100, Israel.
Abstract:
Finding intracellular pathways and molecules that can prevent the proliferation of colon cancer cells can provide significant bases for developing treatments for this disease. Ostreolysin (Oly) is a protein found in the mushroom Pleurotus ostreatus, and we have produced a recombinant version of this protein (rOly).We measured the viability of several colon cancer cells treated with rOly. Xenografts and syngeneic colon cancer cells were injected into in vivo mouse models, which were then treated with this recombinant protein.rOly treatment induced a significant reduction in viability of human and mouse colon cancer cells. In contrast, there was no reduction in the viability of normal epithelial cells from the small intestine. In the search for cellular targets of rOly, we showed that it enhances the anti-proliferative activity of drugs targeting cellular tubulin. This was accompanied by a reduction in the weight and volume of tumours in mice injected with rOly as compared to their respective control mice in two in vivo models.Our results advance the functional understanding of rOly as a potential anti-cancer treatment associated with pro-apoptotic activities preferentially targeting colon cancer cells.
Insights
Recombinant ostreolysin (rOly) from Pleurotus ostreatus mushroom significantly reduces colon cancer cell proliferation. This protein enhances anti-cancer drug efficacy and decreases tumor size in vivo, offering a promising colon cancer treatment strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Colon cancer proliferation necessitates novel therapeutic targets.
- Ostreolysin (Oly), a protein from Pleurotus ostreatus, is explored for anti-cancer properties.
- Recombinant ostreolysin (rOly) was produced for therapeutic investigation.
Purpose of the Study:
- To evaluate the anti-proliferative effects of rOly on colon cancer cells.
- To investigate the in vivo efficacy of rOly in colon cancer models.
- To identify potential molecular mechanisms of rOly's anti-cancer activity.
Main Methods:
- In vitro assessment of rOly's impact on colon cancer cell viability.
- In vivo studies using mouse models with xenograft and syngeneic colon tumors.
- Analysis of rOly's interaction with tubulin-targeting drugs.
Main Results:
- rOly significantly reduced the viability of human and mouse colon cancer cells.
- Normal small intestine epithelial cells showed no reduction in viability upon rOly treatment.
- rOly enhanced the anti-proliferative effects of tubulin-targeting drugs and reduced tumor weight and volume in vivo.
Conclusions:
- rOly exhibits selective anti-proliferative activity against colon cancer cells.
- rOly demonstrates potential as an adjuvant therapy, enhancing conventional treatments.
- These findings support rOly's development as a targeted colon cancer therapeutic agent.
More Related Videos
06:07Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
10:03Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy
Published on: August 2, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy